» Articles » PMID: 24251461

Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons

Overview
Date 2013 Nov 21
PMID 24251461
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome associated with high rates of morbidity and mortality. Due to the lack of evidence-based therapies and increasing prevalence of HFpEF, clinicians are often confronted with these patients and yet have little guidance on how to effectively diagnose and manage them. Here we offer 10 key lessons to assist with the care of patients with HFpEF: (1) Know the difference between diastolic dysfunction, diastolic heart failure, and HFpEF; (2) diagnosing HFpEF is challenging, so be thorough and consider invasive hemodynamic testing to confirm the diagnosis; (3) a normal B-type natriuretic peptide does not exclude the diagnosis of HFpEF; (4) elevated pulmonary artery systolic pressure on echocardiography in the presence of a normal ejection fraction should prompt consideration of HFpEF; (5) use dynamic testing in evaluating the possibility of HFpEF in patients with unexplained dyspnea or exercise tolerance; (6) all patients with HFpEF should be systematically evaluated for the presence of coronary artery disease; (7) use targeted treatment for HFpEF patients based on their phenotypic classification; (8) treat HFpEF patients now by treating their comorbidities; (9) understand the importance of heart rate in HFpEF- lower is not always better; and (10) do not forget to consider rare diseases ("zebras") as causes for HFpEF when evaluating and treating patients. Taken together, these 10 key lessons can help clinicians care for challenging patients with HFpEF while we eagerly await the results of ongoing HFpEF clinical trials and observational studies.

Citing Articles

Evaluating the Prognostic Value of the Modified HFPEF Score in Patients With Heart Failure With Preserved Ejection Fraction.

Jin Y, Geng L, Li Y, Wang K, Xiao B, Wang M Cardiol Res. 2024; 15(5):358-368.

PMID: 39420974 PMC: 11483114. DOI: 10.14740/cr1635.


Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.

Jheng J, Bai Y, Noda K, Huot J, Cook T, Fisher A Circulation. 2024; 150(11):867-883.

PMID: 38804138 PMC: 11384544. DOI: 10.1161/CIRCULATIONAHA.124.068624.


Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling.

Basu S, Yu H, Murrow J, Hallow K PLoS Comput Biol. 2023; 19(11):e1011598.

PMID: 37956217 PMC: 10703410. DOI: 10.1371/journal.pcbi.1011598.


Comparing the Diagnostic Performance of HFA-PEFF and H2FPEF Scoring Systems in Heart Failure with Preserved Ejection Fraction Patients: Insights from the APOLLON Registry.

Mert G, Ozlek B, Ozlek E, Zencirkiran Agus H, Tekinalp M, Kahraman S Anatol J Cardiol. 2023; 27(9):539-548.

PMID: 37655737 PMC: 10510413. DOI: 10.14744/AnatolJCardiol.2023.3345.


From Primary to Tertiary Care: Expert Position Statements to Guide Heart Failure with Preserved Ejection Fraction Diagnosis.

Wan Ahmad W, Mohd Ghazi A, Abdul Ghapar A, Muthusamy T, Liew H, Zainal Abidin I Malays J Med Sci. 2023; 30(1):49-66.

PMID: 36875198 PMC: 9984115. DOI: 10.21315/mjms2023.30.1.5.


References
1.
Burgess M, Jenkins C, Sharman J, Marwick T . Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. J Am Coll Cardiol. 2006; 47(9):1891-900. DOI: 10.1016/j.jacc.2006.02.042. View

2.
Anjan V, Loftus T, Burke M, Akhter N, Fonarow G, Gheorghiade M . Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012; 110(6):870-6. PMC: 3432159. DOI: 10.1016/j.amjcard.2012.05.014. View

3.
Melenovsky V, Borlaug B, Rosen B, Hay I, Ferruci L, Morell C . Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007; 49(2):198-207. DOI: 10.1016/j.jacc.2006.08.050. View

4.
Reil J, Hohl M, Reil G, Granzier H, Kratz M, Kazakov A . Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2012; 34(36):2839-49. PMC: 3858102. DOI: 10.1093/eurheartj/ehs218. View

5.
Borlaug B, Olson T, Lam C, Flood K, Lerman A, Johnson B . Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56(11):845-54. PMC: 2950645. DOI: 10.1016/j.jacc.2010.03.077. View